Medicine has caught up.
Obesity is a chronic disease, not a lack of willpower. A new class of medicines, GLP-1 therapies, works on the hormones that control appetite and fullness. They include semaglutide (sold as Ozempic for diabetes and Wegovy for weight) and tirzepatide (Mounjaro, Zepbound). In December 2025 the World Health Organization issued its first guideline recommending GLP-1 therapies for adults living with obesity, together with healthy eating and activity.
These are prescription medicines. They can cause side effects such as nausea, they aren't right for everyone, and weight often returns when they stop. Start with a doctor, and plan for the long run.